Notable Labs nets $10M for personalized cancer treatment tech

Dollars
Notable Labs tests drug combinations directly on patients' cancer cells to identify the best treatment options.

Notable Labs picked up $10 million in series A financing to advance its drug-testing service that helps oncologists identify the most appropriate combination of drugs for individuals with blood cancers.

CEO Matthew De Silva co-founded Notable after his father was diagnosed with brain cancer and then faced a lack of effective treatment options. “We wanted to try to fight, but didn’t have any treatment options available to us that were compelling,” De Silva said.

While it originally focused on brain cancer, the San Francisco-based startup turned to blood cancers, specifically acute myeloid leukemia and the bone marrow failure disorder, myelodysplastic syndrome. It plans to expand into other blood cancers before going into solid tumors.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Notable’s service involves collecting a blood sample or bone marrow aspirate from a patient and testing individual drugs and combinations on the patient’s cancer cells, as well as their healthy white blood cells, De Silva said. The company comes up with a report of the results, which an oncologist will use to guide treatment decisions for the patient.

“Notable’s purpose is to change the way cancer is treated. Our whole team lives and breathes this mission of developing cancer solutions that are personalized, and that can make an immediate positive impact on patients’ lives … We’re working closely with forward-thinking oncologists and researchers at top U.S. and Canadian cancer centers to make personalized combination treatment a reality,” he said in a statement.

The company is taking a functional rather than genomic approach to personalized therapy—instead of sequencing the genome of a tumor, Notable tests combinations directly on the patient’s cancer cells to find the best treatment.

Since its founding in 2014, Notable has expanded its team and is continuing to invest in automating the analysis of its drug testing. The company is using deep learning to accelerate this analysis so it can give doctors the results as close to real time as possible, De Silva said. The new funding will go toward building out its technology and to bankroll a number of clinical feasibility studies in blood cancers.

Suggested Articles

J&J's DePuy Synthes division has launched a new fixation system to expand treatment options for patients with frail bones in the neck and upper back.

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.